儿童生长激素治疗:挑战、机遇与考量
本文综述儿童生长激素治疗的长期效应、安全性和长效制剂应用等持续关注的问题。文章梳理已批准儿科适应症及其效果与安全性证据,强调个体化治疗目标设定及风险获益讨论的不确定性,并探讨长效生长激素的潜力和未来方向。
要点
- 生长激素治疗长期效应与安全性仍是儿科内分泌领域持续关注的问题。
- 已批准适应症远超替代治疗范围,个体化治疗目标设定存在不确定性。
- 长效生长激素制剂的出现为儿童治疗带来新选择与未来方向。
核心结论
- 儿童生长激素治疗在长期效应、安全性和长效制剂应用方面仍存在诸多挑战与不确定性。
- 个体化治疗目标设定及与患者家庭的风险获益讨论需要进一步明确。
研究设计与样本
- 本文为综述,未报告系统检索范围或样本量。
主要发现
- 长期效应、儿童治疗安全性及长效生长激素制剂是持续关注的问题。
- 如何为个体患者设定合理治疗目标及启动风险获益讨论仍不确定。
- 已批准适应症数量超过替代治疗范围,增加临床决策复杂性。
临床怎么用
- 临床需根据已批准适应症评估生长激素治疗,并个体化设定治疗目标。
- 应与患者及家庭讨论治疗的长期效应、安全性及风险获益。
- 长效生长激素制剂可作为未来治疗选择之一加以考虑。
局限性
- 本文为综述,未报告系统检索策略、纳入标准或样本量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
With long standing demand and popularity, growth hormone treatments continue to be a topic of interest for paediatric endocrinologists and general paediatricians due to ongoing issues regarding their long-term effects, the safety of childhood treatment, and the introduction of long-acting growth hormone preparations in the past decade. Moreover, uncertainty regarding how to approach individual patients and their treatment indications remains, particularly concerning tailored treatment goals and objectives; this uncertainty is further complicated by the multitude of approved indications that surpass substitution therapy. The paediatric endocrinologist thus grapples with pertinent questions, such as what defines reasonable treatment goals for each individual given their indications, and when (and how) to initiate the necessary discussions about risks and benefits with patients and their families. The aim of this Review is to offer advanced physiological concepts of growth hormone function, map out approved paediatric indications for treatment along with evidence on their effects and safety, highlight controversies and complexities surrounding childhood growth hormone treatment, and discuss the potential of long-acting growth hormone and future directions in the realm of childhood growth hormone treatment.
引用
- Tidblad A, Sävendahl L. Childhood growth hormone treatment: challenges, opportunities, and considerations. Lancet Child Adolesc Health. 2024. PMID: 38945136. doi:10.1016/S2352-4642(24)00127-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。